KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Exact Sciences (EXAS) EBT (2016 - 2025)

Exact Sciences has reported EBT over the past 16 years, most recently at -$85.1 million for Q4 2025.

  • Quarterly EBT rose 90.29% to -$85.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$203.9 million through Dec 2025, up 80.32% year-over-year, with the annual reading at -$203.9 million for FY2025, 80.32% up from the prior year.
  • EBT was -$85.1 million for Q4 2025 at Exact Sciences, down from -$17.8 million in the prior quarter.
  • Over five years, EBT peaked at $1.0 million in Q3 2023 and troughed at -$876.0 million in Q4 2024.
  • The 5-year median for EBT is -$104.7 million (2024), against an average of -$145.8 million.
  • Year-over-year, EBT soared 100.69% in 2023 and then plummeted 3688.49% in 2024.
  • A 5-year view of EBT shows it stood at -$224.9 million in 2021, then surged by 42.22% to -$129.9 million in 2022, then skyrocketed by 61.23% to -$50.4 million in 2023, then crashed by 1638.86% to -$876.0 million in 2024, then soared by 90.29% to -$85.1 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's EBT are -$85.1 million (Q4 2025), -$17.8 million (Q3 2025), and -$57000.0 (Q2 2025).